p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)

Bibliography

• Lee JC, Laydon JT, McDonnell PC, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46
   PubMed Web of Science ®Google Scholar
• Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67:909-16
   PubMed Web of Science ®Google Scholar
• Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20
   PubMed Web of Science ®Google Scholar
• Hammaker D, Firestein GS. “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis 2010;69(Suppl 1):i77-82
   PubMed Web of Science ®Google Scholar
• Korb A, Tohidast-Akrad M, Cetin E, Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 2006;54:2745-56
   PubMed Web of Science ®Google Scholar
• CAIR Biosciences GMBH. Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38mapk antibodies, kits and their use. EP1909102; 2008
   Google Scholar
• Available from: www.clinicaltrialsfeeds.org 2011
   Google Scholar
• Available from: www.ambitbio.com 2011
   Google Scholar
• Available from: www.proqinase.com 2011
   Google Scholar
• Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005;12:2979-94
   PubMed Web of Science ®Google Scholar
• Backes AC, Zech B, Felber B, Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov 2008;3:1427-49
   PubMed Web of Science ®Google Scholar
• Backes AC, Zech B, Felber B, Small-molceule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. Expert Opin Drug Discov 2008;12:1409-25
   Google Scholar
• Fabian MA, Biggs WH III, Treiber DK, A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32
   PubMed Web of Science ®Google Scholar
• Fitzgerald CE, Patel SB, Becker JW, Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat Struct Biol 2003;10:764-9
   PubMedGoogle Scholar
• Takeda Pharmaceutical. Medicinal compositions. WO2002100433; 2002
   Google Scholar
• Takeda Pharmaceutical. Novel solid dispersion and manufacturing method thereof. WO2006006691; 2006
   Google Scholar
• Miwatashi S, Arikawa Y, Kotani E, Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 2005;48:5966-79
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical. Condensed imidazole compound and use thereof. EP1832588; 2007
   Google Scholar
• Takeda Pharmaceutical. Fused imidazole compound and use thereof. WO2008133192; 2008
   Google Scholar
• Takeda Pharmaceutical. Fused heterocyclic compound. WO2011021678; 2011
   Google Scholar
• Cadila Healthcare Ltd. Sulfoximine derivatives as p38 map kinase inhibitors. WO2007077574; 2007
   Google Scholar
• Vertex Pharma. Inhibitors of p38. WO9964400; 1999
   Google Scholar
• Karcher SC, Laufer SA. Successful structure-based design of recent p38 MAP kinase inhibitors. Curr Top Med Chem 2009;9:655-76
   PubMed Web of Science ®Google Scholar
• Vertex Pharma. Pyridine derivatives as inhibitors of P38. WO0214281; 2002
   Google Scholar
• Vertex Pharma. Inhibitors of p38. US7205305; 2007
   Google Scholar
• Vertex Pharma. Inhibitors of p38. AU2007200477; 2008
   Google Scholar
• Vertex Pharma. Inhibitors of p38. US7423049; 2008
   Google Scholar
• Vertex Pharma. Pyridine derivatives as inhibitors of p38. AU2007249154; 2008
   Google Scholar
• Vertex Pharma. Inhibitors of p38. US7598277; 2009
   Google Scholar
• Vertex Pharma. Inhibitors of p38. US2009075981; 2009
   Google Scholar
• Vertex Pharma. Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides). WO2010093890; 2010
   Google Scholar
• Vertex Pharma. Inhibitors of p38. US7951809; 2011
   Google Scholar
• Vertex Pharma. Inhibitors of p38. US7919513; 2011
   Google Scholar
• Vertex Pharma. Compositions and methods for treating rheumatoid arthritis. WO2007103468; 2007
   Google Scholar
• Vertex Pharma. Isoquinoline inhibitors of P38. EP1414455; 2004
   Google Scholar
• Vertex Pharma. Inhibitors of p38. US7151101; 2006
   Google Scholar
• Natarajan SR, Wisnoski DD, Singh SB, p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg Med Chem Lett 2003;13:273-6
   PubMed Web of Science ®Google Scholar
• Natarajan SR, Doherty JB. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes. Curr Top Med Chem 2005;5:987-1003
   PubMed Web of Science ®Google Scholar
• Stelmach JE, Liu L, Patel SB, Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2003;13:277-80
   PubMedGoogle Scholar
• Liu L, Stelmach JE, Natarajan SR, SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors. Bioorg Med Chem Lett 2003;13:3979-82
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme. Treatment for Alzheimer's disease and related conditions. WO2005058308; 2005
   Google Scholar
• Hunt JA, Kallashi F, Ruzek RD, p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones. Bioorg Med Chem Lett 2003;13:467-70
   PubMed Web of Science ®Google Scholar
• Bao J, Hunt JA, Miao S, p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bioorg Med Chem Lett 2006;16:64-8
   PubMed Web of Science ®Google Scholar
• Chen MH, Fitzgerald P, Singh SB, Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors. Bioorg Med Chem Lett 2008;18:2222-6
   PubMed Web of Science ®Google Scholar
• Tynebor RM, Chen MH, Natarajan SR, Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors. Bioorg Med Chem Lett 2010;20:2765-9
   PubMedGoogle Scholar
• Merck & Co., Inc. [US]. P38 kinase inhibiting agents. WO2007067478; 2007
   Google Scholar
• Merck & Co., Inc. [US]. Heterobicyclic compounds useful as P38 kinase inhibiting agents. WO2007021710; 2007
   Google Scholar
• Merck Sharp & Dohme. P38 kinase inhibiting agents. WO2010129208; 2010
   Google Scholar
• Tynebor RM, Chen MH, Natarajan SR, Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1. Bioorg Med Chem Lett 2011;21:411-16
   PubMedGoogle Scholar
• Merck & Co., Inc. [US]. Pyrrolo [2, 3-C] pyridine derivatives as P38 kinase inhibiting agents. WO2009152072; 2009
   Google Scholar
• Patel SB, Cameron PM, O'Keefe SJ, The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha. Acta Crystallogr D Biol Crystallogr 2009;65:777-85
   PubMedGoogle Scholar
• Trejo A, Arzeno H, Browner M, Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase. J Med Chem 2003;46:4702-13
   PubMed Web of Science ®Google Scholar
• F. Hoffmann-La Roche. Fused derivatives of pyrazole. WO2005085249; 2005
   Google Scholar
• F. Hoffmann-La Roche. Indazole derivatives and pharmaceutical compositions containing them. WO2005085206; 2005
   Google Scholar
• F. Hoffmann-La Roche. P38 map kinase inhibitors and methods for using the same. WO2007023111; 2007
   Google Scholar
• F. Hoffmann-La Roche. P38 map kinase inhibitors and methods for using the same. WO2007023110; 2007
   Google Scholar
• F. Hoffmann-La Roche. P38 map kinase inhibitors and methods for using the same. WO2007023115; 2007
   Google Scholar
• F. Hoffmann-La Roche. Fused pyrazole as p38 map kinase inhibitors. WO2007023105; 2007
   Google Scholar
• F. Hoffmann-La Roche. P38 map kinase inhibitors and methods for using the same. WO2007023114; 2007
   Google Scholar
• F. Hoffmann-La Roche. Kinase Inhibitors and methods for using the same. WO2008104473; 2008
   Google Scholar
• F. Hoffmann-La Roche. Pyrazolo [3, 4 -D] pyrimidine p38 map kinase inhibitors. WO2008074676; 2008
   Google Scholar
• Roche Palo Alto LLC. Methods of inhibiting p38 with substituted bicyclic pyrimidines. US7449472; 2008
   Google Scholar
• Roche Palo Alto LLC. p38 map kinase inhibitors and methods for using the same. US7517901; 2009
   Google Scholar
• Goldstein DM, Gabriel T. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 2005;5:1017-29
   PubMed Web of Science ®Google Scholar
• F.Hoffmann-La Roche. Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones. WO2005047284; 2005
   Google Scholar
• F. Hoffmann-La Roche. Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same. WO2008055842; 2008
   Google Scholar
• Roche Palo Alto LLC. Imidazo-substituted compounds as p38 kinase inhibitors. US7081462; 2006
   Google Scholar
• Roche Palo Alto LLC. Imidazo-substituted compounds as P38 kinase inhibitors. US7285561; 2007
   Google Scholar
• Roche Palo Alto LLC. Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones. US7348331; 2008
   Google Scholar
• Hill RJ, Dabbagh K, Phippard D, Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008;327:610-19
   PubMed Web of Science ®Google Scholar
• Cohen SB, Cheng TT, Chindalore V, Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-44
   PubMed Web of Science ®Google Scholar
• Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005;5:929-39
   PubMed Web of Science ®Google Scholar
• Mavunkel BJ, Chakravarty S, Perumattam JJ, Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue. Bioorg Med Chem Lett 2003;13:3087-90
   PubMed Web of Science ®Google Scholar
• Scios, Inc. Indole-type inhibitors of p38 kinase. US6890938; 2005
   Google Scholar
• Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase. US6867209; 2005
   Google Scholar
• Scios, Inc. Inhibitors of p38 kinase. US7291613; 2007
   Google Scholar
• Scios, Inc. Pharmaceutical formulations of an indole-type derivative and related methods of use. WO2008024391; 2008
   Google Scholar
• Scios, Inc. Indole-type derivatives as inhibitors of P38 kinase. US7488744; 2009
   Google Scholar
• Scios, Inc. Azaindole derivatives as inhibitors of P38 kinase. WO2006112828; 2006
   Google Scholar
• Tan X, Tester RW, Luedtke GR, Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles. Bioorg Med Chem Lett 2010;20:828-31
   PubMedGoogle Scholar
• Navas TA, Nguyen AN, Hideshima T, Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006;20:1017-27
   PubMed Web of Science ®Google Scholar
• Scios, Inc. Method of treating myelodysplastic syndromes. US2006258582; 2006
   Google Scholar
• Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition. US2006052390; 2006
   Google Scholar
• Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase. US2006079461; 2006
   Google Scholar
• Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008;47:409-14
   PubMed Web of Science ®Google Scholar
• Mavunkel BJ, Perumattam JJ, Tan X, Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitors. Bioorg Med Chem Lett 2010;20:1059-62
   PubMed Web of Science ®Google Scholar
• Luedtke GR, Schinzel K, Tan X, Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules. Bioorg Med Chem Lett 2010;20:2556-9
   PubMedGoogle Scholar
• Scios, Inc. Heterocyclic amides and sulfonamides. WO2005033072; 2005
   Google Scholar
• Scios, Inc. Quinazoline derivatives as medicaments. US2005220784; 2005
   Google Scholar
• Murali Dhar TG, Wrobleski ST, Lin S, Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds. Bioorg Med Chem Lett 2007;17:5019-24
   PubMedGoogle Scholar
• Squibb Bristol Myers Co. Heterobicyclic compounds useful as kinase inhibitors. US7943617; 2011
   Google Scholar
• Liu C, Lin J, Pitt S, Benzothiazole based inhibitors of p38alpha MAP kinase. Bioorg Med Chem Lett 2008;18:1874-9
   PubMed Web of Science ®Google Scholar
• Squibb Bristol Myers Co. Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors. WO2007016392; 2007
   Google Scholar
• Squibb Bristol Myers Co. Phenyl-substituted pyrimidine compounds useful as kinase inhibitors. WO2006084017; 2006
   Google Scholar
• Squibb Bristol Myers Co. Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors. WO2009155388; 2009
   Google Scholar
• Squibb Bristol Myers Co. Triazolopyridine compounds useful as kinase inhibitors. WO2009155389; 2009
   Google Scholar
• Leftheris K, Ahmed G, Chan R, The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J Med Chem 2004;47:6283-91
   PubMed Web of Science ®Google Scholar
• Squibb Bristol Myers Co. N-heterocyclic inhibitors of TNF-alpha expression. US7479495; 2009
   Google Scholar
• Lin TH, Metzger A, Diller DJ, Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther 2006;318:495-502
   PubMed Web of Science ®Google Scholar
• Liu C, Wrobleski ST, Lin J, 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase. J Med Chem 2005;48:6261-70
   PubMed Web of Science ®Google Scholar
• Squibb Bristol Myers Co. N-heterocyclic inhibitors of TNF-alpha expression. US7253174; 2007
   Google Scholar
• Squibb Bristol Myers Co. N-heterocyclic inhibitors of tnf-alpha expression. US2008015185; 2008
   Google Scholar
• Das J, Moquin RV, Pitt S, Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Bioorg Med Chem Lett 2008;18:2652-7
   PubMed Web of Science ®Google Scholar
• Squibb Bristol Myers Co. Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors. WO2006020904; 2006
   Google Scholar
• Squibb Bristol Myers Co. Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors. US2006035886; 2006
   Google Scholar
• Squibb Bristol Myers Co. Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein. US2009312331; 2009
   Google Scholar
• Squibb Bristol Myers Co. Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-F][1,2,4]triazine-6-carboxamide and novel stable forms produced therein. EP1874778; 2009
   Google Scholar
• Squibb Bristol Myers Co. Tablet formulation for P38 inhibitor and method. WO2010120963; 2010
   Google Scholar
• Hynes J Jr, Dyckman AJ, Lin S, Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors. J Med Chem 2008;51:4-16
   PubMed Web of Science ®Google Scholar
• Liu C, Lin J, Wrobleski ST, Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[ 1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem 2010;53:6629-39
   PubMed Web of Science ®Google Scholar
• Sack JS, Kish KF, Pokross M, Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase. Acta Crystallogr D Biol Crystallogr 2008;D64:705-10
   PubMedGoogle Scholar
• Squibb Bristol Myers Co. Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors. WO2005077945; 2005
   Google Scholar
• Squibb Bristol Myers Co. Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors. US2009149650; 2009
   Google Scholar
• Squibb Bristol Myers Co. Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors. US7491725; 2009
   Google Scholar
• Hynes J Jr, Wu H, Pitt S, The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. Bioorg Med Chem Lett 2008;18:1762-7
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharma. Methods of treating copd and pulmonary hypertension. WO2005018624; 2005
   Google Scholar
• Boehringer Ingelheim Pharma. Methods of treating COPD and pulmonary hypertension. US2005148555; 2005
   Google Scholar
• Boehringer Ingelheim Pharma. New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders. WO2006015775; 2006
   Google Scholar
• Boehringer Ingelheim Pharma. New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders. WO2008049842; 2008
   Google Scholar
• Cogan DA, Aungst R, Breinlinger EC, Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2008;18:3251-5
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharma. 7-(Piperazine-1-ymethyl)-1H-indole-2-carboxylic acid (phenyl)-amide derivatives and allied compounds as P38 map kinase inhibitors for the treatment of respiratory diseases. WO2010026096; 2010
   Google Scholar
• Goldberg DR, Hao MH, Qian KC, Discovery and optimization of p38 inhibitors via computer-assisted drug design. J Med Chem 2007;50:4016-26
   PubMed Web of Science ®Google Scholar
• Bayer Pharmaceuticals Corp. Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas. EP1616865; 2006
   Google Scholar
• Bayer Healthcare LLC. [omega]-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors. US7897623; 2011
   Google Scholar
• Lilly Co. Eli. Pyrazole-isoquinoline urea derivatives as P38 kinase inhibitors. WO2007053346; 2007
   Google Scholar
• Pulmagen Therapeutics Inflamma. Pyridylurea derivatives and their therapeutic use. WO2010131030; 2010
   Google Scholar
• Pulmagen Therapeutics Inflamma. Triazolopyridine derivatives as P38 map kinase inhibitors. WO2010094956; 2010
   Google Scholar
• Pulmagen Therapeutics Inflamma. Pyrimidopyridazine derivatives useful as P38 mapk inhibitors. WO2010094955; 2010
   Google Scholar
• Pulmagen Therapeutics Inflamma. New combinations for the treatment of asthma. WO2011012897; 2010
   Google Scholar
• Pharmacia & Upjohn Co. LLC. Novel triazolopyridine compounds for the treatment of inflammation. WO2006018727; 2006
   Google Scholar
• Pharmacia & Upjohn Co. LLC. Novel triazolopyridine compounds. WO2006018735; 2006
   Google Scholar
• Pfizer Ltd. Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors. WO2006018718; 2006
   Google Scholar
• Pfizer Ltd. Triazolopyridine compounds. WO2007091152; 2007
   Google Scholar
• Jerome KD, Rucker PV, Xing L, Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition. Bioorg Med Chem Lett 2010;20:469-73
   PubMed Web of Science ®Google Scholar
• Xing L, Shieh HS, Selness SR, Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804. Biochemistry 2009;48:6402-11
   PubMed Web of Science ®Google Scholar
• Pharmacia & Upjohn Co. LLC. Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-YL]-N-(2-hydroxyethyl)-4-methylbenzamide. WO2006040649; 2006
   Google Scholar
• Pharmacia Corp. Diaryl substituted pyridinones. US2006211694; 2006
   Google Scholar
• Pharmacia Corp. Substituted pyrimidinones. US7795271; 2010
   Google Scholar
• Pfizer Prod, Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives. WO2007091176; 2007
   Google Scholar
• Pfizer Prod, Inc. Methods of treating acute inflammation in animals with p38 map kinase inhibitors. WO2005060967; 2005
   Google Scholar
• Walker JK, Selness SR, Devraj RV, Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg Med Chem Lett 2010;20:2634-8
   PubMed Web of Science ®Google Scholar
• Angell RM, Angell TD, Bamborough P, Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett 2008;18:4433-7
   PubMed Web of Science ®Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2006110298; 2006
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2006104915; 2006
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2006104889; 2006
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2007147109; 2007
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2007147104; 2007
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2007147103; 2007
   Google Scholar
• Glaxo Group Ltd. Compounds. US7674789; 2010
   Google Scholar
• Glaxo Group Ltd. Compounds. US7678801; 2011
   Google Scholar
• Anand P, Shenoy R, Palmer JE, Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 2011;15(12):1040-8
   PubMedGoogle Scholar
• Glaxo Group Ltd. Novel process and formulations. WO2007059500; 2007
   Google Scholar
• Smithkline Beecham Corp. 3- aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as P38 kinase inhibitors. WO2005014550; 2005
   Google Scholar
• Aston NM, Bamborough P, Buckton JB, p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem 2009;52:6257-69
   PubMed Web of Science ®Google Scholar
• Amgen, Inc. Quinazoline and pyridopyrimidine derivatives as P38 kinase inhibitors. WO2008011032; 2008
   Google Scholar
• Pettus LH, Wurz RP. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008. Curr Top Med Chem 2008;8:1452-67
   PubMed Web of Science ®Google Scholar
• Herberich B, Cao GQ, Chakrabarti PP, Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold. J Med Chem 2008;51:6271-9
   PubMedGoogle Scholar
• Amgen, Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof. WO2010042649; 2010
   Google Scholar
• Amgen, Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as P38 modulators and methods of use thereof. WO2010025202; 2010
   Google Scholar
• Amgen, Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof. WO2010042646; 2010
   Google Scholar
• Amgen, Inc. Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. WO2010025201; 2010
   Google Scholar
• Pettus LH, Xu S, Cao GQ, 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem 2008;51:6280-92
   PubMedGoogle Scholar
• Amgen, Inc., amg. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators, process for their preparation, and their pharmaceutical use. WO2008136948; 2008
   Google Scholar
• Amgen, Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use. WO2008137176; 2008
   Google Scholar
• Amgen, Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof. WO2008045393; 2008
   Google Scholar
• Amgen, Inc. Pyrazolo-pyrazinone compounds and methods of use thereof. WO2009117156; 2009
   Google Scholar
• Amgen, Inc. Pyrazolo-pyridinone derivatives and methods of use. WO2009055033; 2009
   Google Scholar
• Amgen, Inc. Triazole fused heteroaryl compounds as P38 kinase inhibitors. WO2009038784; 2009
   Google Scholar
• Pettus LH, Wurz RP, Xu S, Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem 2010;53:2973-85
   PubMed Web of Science ®Google Scholar
• Almirall Lab. New pyridin-3-amine derivatives. WO2007096072; 2007
   Google Scholar
• Lumeras W, Caturla F, Vidal L, Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase. J Med Chem 2009;52:5531-45
   PubMed Web of Science ®Google Scholar
• Almirall Lab. 1, 7-naphthyridine derivatives as P38 map kinase inhibitors. WO2008017461; 2008
   Google Scholar
• Almirall Lab. New 4,8-diphenyl-polyazanaphthalene derivatives. WO2008131922; 2008
   Google Scholar
• Almirall Lab. New 3-([1,2,4]triazolo[4,3-A]pyridin-7-YL)benzamide derivatives. WO2008107125; 2008
   Google Scholar
• Almirall Lab. New substituted spiro[cycloalkyl-1,3′-indol]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors. WO2009124692; 2009
   Google Scholar
• Almirall Lab. New substituted indolin-2-one derivatives and their use as P39 mitogen-activated kinase inhibitors. WO2009132774; 2009
   Google Scholar
• Almirall Lab. New 7-phenyl-[1,2,4]triazolo[4,3-A]pyridin-3(2H)-one derivatives. WO2011057757; 2011
   Google Scholar
• Revesz L, Blum E, Di Padova FE, Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity. Bioorg Med Chem Lett 2006;16:262-6
   PubMed Web of Science ®Google Scholar
• Triad Therapeutics, Inc. Bicyclic heterocyclic P-38 kinase inhibitors. WO2005063766; 2005
   Google Scholar
• Triad Therapeutics, Inc. 5-Membered heterocycle-based P38 kinase inhibitors. WO2005009973; 2005
   Google Scholar
• Triad Therapeutics, Inc. p-38 kinase inhibitors. WO2005012241; 2005
   Google Scholar
• Triad Therapeutics, Inc. 5-membered heterocycle-based P-38 inhibitors. WO2005000298; 2005
   Google Scholar
• Novartis AG. P-38 inhibitors. US7652044; 2010
   Google Scholar
• Novartis AG. 5-membered heterocycle-based p38 kinase inhibitors. US7863314; 2011
   Google Scholar
• Revesz L, Blum E, Di Padova FE, SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity. Bioorg Med Chem Lett 2004;14:3601-5
   PubMed Web of Science ®Google Scholar
• Laufer SA, Ahrens GM, Karcher SC, Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors. J Med Chem 2006;49:7912-15
   PubMed Web of Science ®Google Scholar
• Merckle GMBH. Dibenzocycloheptane compounds and pharmaceuticals containing these compounds. WO2006120010; 2006
   Google Scholar
• Ottosen ER, Sorensen MD, Bjorkling F, Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem 2003;46:5651-62
   PubMed Web of Science ®Google Scholar
• CAIR Biosciences GMBH. Dibenzocycloheptanone derivatives and pharmaceutical agents containing said compounds. WO2010040843; 2010
   Google Scholar
• Arqule, Inc. 1,4-Disubstituted naphtalenes as inhibitors of P38 map kinase. WO2006010082; 2006
   Google Scholar
• Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of P38 map kinase. WO2006044869; 2006
   Google Scholar
• Array Biopharma, Inc. 38 inhibitors and methods of use thereof. WO2006122230; 2006
   Google Scholar
• Array Biopharma, Inc. P38 inhibitors and methods of use thereof. WO2007126871; 2007
   Google Scholar
• Uriachy Compania SAJ. Heterocyclic compounds. WO2006013095; 2006
   Google Scholar
• Uriachy Compania SAJ. Bicyclic derivatives as P38 inhibitors. WO2007000340; 2007
   Google Scholar
• Uriachy Compania SAJ. Bicyclic derivatives as P38 kinase inhibitors. WO2007000339; 2007
   Google Scholar
• Uriachy Compania SAJ. Bicyclic derivatives as P38 kinase inhibitors. WO2007000337; 2007
   Google Scholar
• Palau Pharma SA. Pyrazoloisoquinoline derivatives. WO2007060198; 2007
   Google Scholar
• Dominguez C, Tamayo N, Zhang D. p38 Inhibitors: beyond pyridinylimidazoles. Expert Opin Ther Patents 2005;15:801-16
   Web of Science ®Google Scholar